39 related articles for article (PubMed ID: 38650598)
1. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Bastos-Oreiro M; Muntañola A; Panizo C; Gonzalez-Barca E; de Villambrosia SG; Córdoba R; López JLB; González-Sierra P; Terol MJ; Gutierrez A; Grande C; Ramirez MJ; Iserte L; Perez E; Navarro B; Gomez P; Salar A; Luzardo H; López A; Del Campo R; García-Belmonte D; Vida MJ; Infante M; Queizan-Hernandez JA; Novelli S; Moreno M; Penarrubia M; Gómez J; Domingo A; Donato E; Viguria MC; López F; Rodriguez MJ; Pardal E; Noriega V; Andreu R; Peñalver J; Martín A; Caballero D; López-Guillermo A
Ann Hematol; 2020 Apr; 99(4):799-808. PubMed ID: 32076827
[TBL] [Abstract][Full Text] [Related]
2. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Bastos-Oreiro M; Gutierrez A; Iacoboni G; López Corral L; Reguera JL; Abrisqueta P; Delgado J; Terol MJ; Hernani R; Martínez N; Ortíz V; Bailen R; Gomez-Centurión I; Caballero A; Sanz J; Guerra Domínguez L; Luzardo H; Mussetti A; Jiménez-Ubieto A; Sancho JM; Sureda A; Pérez A; Barba P; Kwon M; Martín García-Sancho A
Transplant Cell Ther; 2023 Dec; 29(12):747.e1-747.e10. PubMed ID: 37659694
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
Feng YX; Su LP
Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
[No Abstract] [Full Text] [Related]
5. New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Bastos-Oreiro M; Abrisqueta P; Gutierrez A; Jiménez Ubieto A; Poza M; Fernanez-Caldas P; LLacer MJ; Gonzalez de Villambrosia S; Córdoba R; López A; Ceballos E; Navarro B; Muntañola A; Donato E; Diez-Baeza E; Escoda L; Luzardo H; Peñarrubia MJ; García Belmonte D; Pardal E; Lozada C; Martín García-Sancho A
Hemasphere; 2024 Apr; 8(4):e70. PubMed ID: 38650598
[No Abstract] [Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML; Testi AM; Foà R
Br J Haematol; 2020 Jun; 189(5):826-843. PubMed ID: 32141616
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Gonzalez Barca E
J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068428
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
11. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
